Active-control equivalence trials and antihypertensive agents

被引:33
作者
McAlister, FA
Sackett, DL
机构
[1] Univ Alberta, Div Gen Internal Med, Edmonton, AB T6G 2M7, Canada
[2] Inst Hlth econ, Edmonton, AB, Canada
[3] Trout Res & Educ Ctr, Irish Lake, ON, Canada
关键词
D O I
10.1016/S0002-9343(01)00900-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: To identify methodological features that affect the validity of conclusions drawn from active-control equivalence trials and to apply these criteria to recently published trials comparing antihypertensive agents from different classes. METHODS: Standard methodological criteria for randomized clinical trials and six additional methodological features that affect the validity of active-control equivalence trials were applied to four recently published large trials that compared different antihypertensive classes and that concluded that their results showed equivalence. RESULTS: All four of these trials fulfilled standard criteria for randomized trials. However, none fulfilled all of the six additional methodological criteria that affect the validity of active-control equivalence trials, one fulfilled five criteria, two fulfilled two criteria, and one failed to fulfill any of the criteria. CONCLUSION: Standard methodological criteria for evaluating superiority trials are inadequate for the interpretation of active-control equivalence trials. The methodological criteria outlined in this article for judging the validity of active-control equivalence trials are not specific to antihypertensive trials and may be applied to trials that test a wide variety of interventions. (C) 2001 by Excerpta Medica, Inc.
引用
收藏
页码:553 / 558
页数:6
相关论文
共 29 条
  • [1] PROVING THE NULL HYPOTHESIS IN CLINICAL-TRIALS
    BLACKWELDER, WC
    [J]. CONTROLLED CLINICAL TRIALS, 1982, 3 (04): : 345 - 353
  • [2] Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
    Brown, MJ
    Palmer, CR
    Castaigne, A
    de Leeuw, PW
    Mancia, G
    Rosenthal, T
    Ruilope, LM
    [J]. LANCET, 2000, 356 (9227) : 366 - 372
  • [3] MORBIDITY AND MORTALITY IN THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP-HYPERTENSION)
    DAHLOF, B
    LINDHOLM, LH
    HANSSON, L
    SCHERSTEN, B
    EKBOM, T
    WESTER, PO
    [J]. LANCET, 1991, 338 (8778) : 1281 - 1285
  • [4] WHEN WAS A NEGATIVE CLINICAL-TRIAL BIG ENOUGH - HOW MANY PATIENTS YOU NEEDED DEPENDS ON WHAT YOU FOUND
    DETSKY, AS
    SACKETT, DL
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (04) : 709 - 712
  • [5] Scientific and ethical issues in equivalence trials
    Djulbegovic, B
    Clarke, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (09): : 1206 - 1208
  • [6] SIGNIFICANCE TESTING TO ESTABLISH EQUIVALENCE BETWEEN TREATMENTS, WITH SPECIAL REFERENCE TO DATA IN FORM OF 2 X 2 TABLES
    DUNNETT, CW
    GENT, M
    [J]. BIOMETRICS, 1977, 33 (04) : 593 - 602
  • [7] Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases
    Ellenberg, SS
    Temple, R
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) : 464 - 470
  • [8] Claims of equivalence in medical research: Are they supported by the evidence?
    Greene, WL
    Concato, J
    Feinstein, AR
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (09) : 715 - 722
  • [9] Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension:: the Nordic Diltiazem (NORDIL) study
    Hansson, L
    Hedner, T
    Lund-Johansen, P
    Kjeldsen, SE
    Lindholm, LH
    Syvertsen, JO
    Lanke, J
    de Faire, U
    Dahlöf, B
    Karlberg, BE
    [J]. LANCET, 2000, 356 (9227) : 359 - 365
  • [10] Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial
    Hansson, L
    Lindholm, LH
    Niskanen, L
    Lanke, J
    Hedner, T
    Niklason, A
    Luomanmäki, K
    Dahlöf, B
    de Faire, U
    Mörlin, C
    Karlberg, BE
    Wester, PO
    Björck, JE
    [J]. LANCET, 1999, 353 (9153) : 611 - 616